TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥ 18 years of age~* Rheumatoid arthritis for at least 3 months~* Inadequate response to previous or current treatment with at least one anti-TNF-alpha agent~* Receiving either leflunomide or methotrexate for ≥ 12 weeks, with a stable dose for the last 4 weeks~* Swollen joint count (SJC) ≥ 4 (66 joint count) and tender joint count (TJC) ≥ 4 (68 joint count) at screening and baseline.~* CRP ≥ 0.6 mg/dL using a high-sensitivity assay.~* Positive rheumatoid factor or positive anti-CCP antibody or both.~Exclusion Criteria:~* Rheumatic autoimmune disease or inflammatory joint disease, other than RA~* Any surgical procedure in past 12 weeks,or planned within 48 weeks of baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ocrelizumab 200 mg x 2 IV + Non-Biologic DMARD Therapy (Type: EXPERIMENTAL): Participants will receive 2 intravenous (IV) infusions of 200 milligram (mg) of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
- Ocrelizumab 500 mg x 2 IV + Non-Biologic DMARD Therapy (Type: EXPERIMENTAL): Participants will receive 2 IV infusions of 500 mg of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
- Placebo x 2 IV + Non-Biologic DMARD Therapy (Type: PLACEBO_COMPARATOR): Participants will receive ocrelizumab matching placebo IV in two infusions, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation in Polymorphic Light Eruption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of PLE by typical patient history, typical histology of skin lesions and/or positive photo provocation results~Exclusion Criteria:~* Allergy or intolerance to Oleovit D3 or Coconut/palm kernel~* Presence or history of malignant skin tumors~* Dysplastic melanocytic nevus syndrome~* Photosensitive diseases such as porphyria, chronic actinic dermatitis, xeroderma pigmentosum, and basal cell nevus syndrome; autoimmune disorders such as lupus erythematosus or dermatomyositis~* Sarcoid~* Renal dysfunction~* Psychiatric disorder~* Pregnancy or breastfeeding~* Topical treatment with vitamin D derivates within 3 months~* Oral treatment with vitamin D within 6 months~* Antinuclear antibodies such as anti-ds-DNA or anti- Ro/La~* 25-hydroxy vitamin D serum levels \> 30ng/ml at screening visit~* Serum hypercalcemia \> 2,65 nmol/L~* Treatment with thiazides or glycosides~* Systemic treatment with steroids and/or other immunosuppressive drugs within 4 weeks~* UV exposure in test fields within 8 weeks before the start of the study~* General poor health status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients whose physicians plan to prescribe low-dose hCG for ovarian stimulation~2. Age 18-46~3. Negative serum hCG prior to start of COH~4. BMI \>18 and \<35~5. Plan for ejaculated sperm use~6. Plan for PGT testing with euploid embryo transfer~Exclusion Criteria:~1. Administration of low-dose hCG during frozen embryo transfer cycle~2. Concomitant Menopur administration during ovarian stimulation or during frozen embryo transfer cycle~3. BMI \<18 or \>35~4. Age \<18 or \>46~5. Presence of hydrosalpinxes that communicate with the endometrial cavity~6. Diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), and persistent endometrial fluid~7. Uncorrected uterine factor infertility (uterine anomaly, submucosal myomas, uterine septum)~8. Male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable)~9. Use of surgical procedures to obtain sperm~10. Couples undergoing IVF for fertility preservation with no immediate plan for subsequent FET (embryo banking)~11. Personal history of repeated pregnancy loss (two or more unexplained clinical losses defined by presence of fetal heartbeat)~12. Declination of PGT testing

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): to remain on current dose of low dose hCG
- Intervention Group (Type: EXPERIMENTAL): increased dose of low dose hCG prescribed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Metastatic UC (Urothelial Carcinoma) including cancers of the renal pelvis, ureters, urinary bladder, and urethra~* Will be receiving atezolizumab for the treatment of inoperable locally-advanced or metastatic UC, per the decision of the treating physician~* Have adequate hematologic and end-organ functions~* Have had no prior palliative chemotherapy for inoperable locally-advanced or metastatic UC and are clinically ineligible (unfit) for cisplatin-based chemotherapy~Exclusion Criteria:~* Have received prior immune checkpoint therapy~* Are pregnant or breastfeeding~* Are included in any other trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: DepoCyt for Active Lymphomatous or Leukemic Meningitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologically confirmed, or radiographic evidence for lymphomatous or leukemic meningitis. If the CSF cytology is negative, patients must have MRI/CT brain and clinical findings consistent with neoplastic meningitis.~* Karnofsky Performance Score of 60 or above.~* Age ≥ 18 years.~* Patients must have adequate hematologic, renal and liver function. Laboratory~* Absolute neutrophil count (ANC) ≥ 1,500/mm3 or white blood cell count \> 3,000/mm3~* Platelet count ≥ 100, 000/mm3~* BUN and serum creatinine must be ≤ 1.5 times upper limit of laboratory normal~* Total and direct serum bilirubin must be ≤ 1.5 times upper limit of laboratory normal~* SGOT and SGPT ≤ 3.0 times upper limit of laboratory normal~* Alkaline phosphatase derived from liver ≤ 2.0 times upper limit of laboratory normal~* No uncontrolled infection other than human immunodeficiency virus that is being treated with anti-retroviral therapy~* Patients who have had prior CNS radiation, prior intrathecal methotrexate, and prior CNS prophylaxis with intrathecal or intravenous cytarabine or methotrexate are eligible~* Written informed consent~Exclusion Criteria:~* Experimental/Investigational chemotherapy, immunotherapy, or biologic therapy within four weeks prior to study~* Concurrent systemic chemotherapy with high dose methotrexate, high dose cytarabine, or high dose thiotepa (they cross the blood brain barrier at high levels)~* Patients receiving whole brain radiotherapy or craniospinal irradiation~* Previous (less than 2 years from diagnosis) or concurrent malignancies at other sites with the exception of fully treated carcinoma in situ of the cervix, basal cell carcinoma of the skin, and squamous cell carcinoma of the skin, or prostate cancer not requiring ongoing chemotherapy~* Pregnant or lactating women~* Known active meningeal infection~* Evidence of obstructive hydrocephalus requiring neurosurgical intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lymphomatous (Type: EXPERIMENTAL): Subjects with Lymphomatous Meningitis
- Leukemic (Type: EXPERIMENTAL): Subjects with Leukemic Meningitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of 18 at time of first visit.~2. HIV uninfected on the basis of a negative HIV Rapid Test~3. Possible non-occupational exposure to HIV-1, recent enough to permit receiving the first dose of study medication within 72 hours from the end of the exposure.~Exclusion Criteria:~1. Women who are actively trying to become pregnant.~2. Pregnancy and/or Breastfeeding.~3. Known self report of Chronic Hepatitis B infection or prior antiretroviral therapy for hepatitis B.~4. Known intolerance or allergy to study drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Atazanavir, Ritonavir, Truvada (Type: OTHER): Open Label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Mechanical Stress Effects on the Cardiovascular Adaptations of Peripheral Arterial Calcifications Among Athletes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for athletic and sedentary volunteers:~* The volunteer must have given his/her informed and signed consent~* The volunteer must be insured or beneficiary of a health insurance plan~* Volunteers without cardiovascular disease, glucose regulation disorders or known renal disease~Inclusion Criteria for athletic volunteers only:~* Ongoing athletic activity for the past 10 years~* Athletic activity at the regional level for the past 5 years~* Practices one of the three following sports: marathon, trail running, cycling.~Exclusion Criteria for athletic and sedentary volunteers:~* The volunteer is participating in another study~* The volunteer is in an exclusion period determined by a previous study~* The volunteer is under judicial protection, under tutorship or curatorship~* The volunteer refuses to sign the consent~* It is impossible to correctly inform the volunteer~* The volunteer is pregnant, parturient, or breastfeeding~* Tobacco use~* Contraindications for the practice of physical activity (joint, heart or other)~* Intercurrent pathology~* First degree family history of cardiovascular disease~* Known dyslipidemia (including cholesterol)~* Glucose tolerance abnormalities (prediabetes or diabetes)~* Treatment with certain drugs used for treating erectile dysfunction: Sildefanil (Viagra), Tadalafil (Cialis), Vardenafil (Levitra) and yohimbine (Yohimbine Houde and Yocoral)~Exclusion Criteria for sedentary volunteers only:~* More than two hours of athletic activity per week~* History of intense athletic training~* Body mass index \>= 25 kg/m\^2

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Upper-body athletes (Type: None): This group includes swimmers, rowers or kayakers with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
- Lower-body athletes (Type: None): This group includes runners (marathon or trail) and cyclists with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
- Sedentary volunteers (Type: None): This group of healthy volunteers does not participate in athletic activity for more than two hours per week. They are matched by age and sex with the athletic groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Having successfully completed parent study B7601003.~* Clinical diagnosis of Parkinson's disease.~* Able to refrain from any Parkinson's disease medication not permitted by the protocol.~Exclusion Criteria:~* Female of childbearing potential.~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality.~* Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 87 Years
- Healthy Volunteers: f

Study Arms:
- 1 mg QD to 15 mg QD PF-06649751 (Type: EXPERIMENTAL): Up titration from 1 mg QD to 15 mg QD PF-06649751
- 3 mg QD to 15 mg QD PF-06649751 (Type: EXPERIMENTAL): Up titration from 3 mg QD to 15 mg QD PF-06649751
- 7 mg QD to 15 mg QD PF-06649751 (Type: EXPERIMENTAL): Up titration from 7 mg QD to 15 mg QD PF-06649751
- 15 mg QD PF-06649751 (Type: EXPERIMENTAL): 15 mg QD PF-06649751 remains at 15 mg QD PF-06649751
- 1 mg to 7 mg QD PF-06649751 (Type: EXPERIMENTAL): Up titration from 1 to 7 mg QD PF-06649751 if de-escalated in parent study
- 3 mg QD to 7 mg QD PF-06649751 (Type: EXPERIMENTAL): Up titration from 3 to 7 mg QD PF-06649751 if de-escalated in parent study
- 7 mg QD to 7 mg QD PF-06649751 (Type: EXPERIMENTAL): 7 mg QD remains at 7 mg QD PF-06649751 if de-escalated in parent study
- 15 mg to 7 mg QD PF-06649751 (Type: EXPERIMENTAL): 15 mg QD de-escalated to 7 mg QD in parent study B7601003 remain at 15 mg QD PF-06649751

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Dietary Fiber on Food Liking

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) between 18.5 to 24.9 kg/m\^2~* Unrestrained eater (\<12 on Three Factor Eating Questionnaire \[TFEQ\])~* report liking turkey or ham sandwiches, brownies, grapes, and potato chips (rate all items \>50mm on a visual analogue scale \[VAS\]).~* Report regularly eating before 10 am~* Can completed all sessions within 6 weeks of the screening session.~Exclusion Criteria:~* Report binge eating~* Report a medical condition that influences eating~* Report food allergies to the study foods~* Currently smoke~* Report dietary restrictions~* Report not liking brownies~* Report currently taking a medication that effects appetite~* Report being pregnant or breast-feeding~* Report being an athlete in training.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Regular Brownie (Type: OTHER): Regular Brownie For the regular brownie condition (RB), participants will consume the brownie preload and then consume a meal 20 minutes later.
- Psyllium Brownie (Type: OTHER): For the psyllium brownie (PG), participants will consume a psyllium brownie and then consume a meal 20 minutes later.
- β-glucan Brownie (Type: OTHER): For the β-glucan Brownie (BG), participants will consume a β-glucan Brownie preload and then consume a meal 20 minutes later

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: DASH-Sodium Trial in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* White, black, Hispanic, and Asian~* SBP in the upper one-third of the distribution for their given sex, age, and height~Exclusion Criteria:~* Pre-existing lipid disorders, abnormal liver or kidney function~* Taking medications that alter mineral absorption or metabolism, affect blood pressure or lipids~* If subjects are taking dietary supplements and refuse to discontinue them 2 months prior to the study.~* Taking non-prescription illegal drugs, smoke, or drink alcohol~* Pregnancy~* Carry an epi pen for food-related allergies

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- DASH diet-Low Na diet (Type: EXPERIMENTAL): DASH style diet, low sodium (1500 mg/d).
- DASH diet-High Na diet (Type: ACTIVE_COMPARATOR): DASH style diet, high sodium (3500 mg/d).
- Usual diet-Low Na diet (Type: ACTIVE_COMPARATOR): Diet reflecting typical dietary pattern of American adolescents, low sodium (1500 mg/d).
- Usual diet-High Na diet (Type: ACTIVE_COMPARATOR): Diet reflecting typical dietary pattern of American adolescents, high sodium (3500 mg/d).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Perioperative Goal Directed Therapy Using Flotrac Improve Outcomes in Esophagectomy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age or older~* Patients undergoing primary resection of esophageal cancer and resultant esophagectomy.~Exclusion Criteria:~* Patients \< 55kg or \> 140 kg, based on literature regarding accuracy of FloTrac.~* Patients with sustained preoperative dysrhythmias, based on literature regarding accuracy of FloTrac (atrial flutter and/or atrial fibrillation).~* Patients with diagnosed NYHA class III-IV failure or documented EF \< 30%~* Patients who are unable/unwilling to consent for study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Goal Directed Therapy (Type: ACTIVE_COMPARATOR): In this arm patient will have the FloTrac monitor and a Goal Directed Therapy algorithm will be used to manage blood pressures.
- Usual Care (Type: NO_INTERVENTION): Standard of care will be used to manage blood pressures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: To be considered for enrollment, subjects must:~* have been randomized in protocol 012-VWAV06;~* have signed and dated an IRB-approved written informed consent to participate in 012-VWAV06 as well as this study;~* be willing to comply with all aspects of the evaluation schedule over a period of 60 months post device insertion;~* allow representatives of the sponsor, designated Clinical Research Organization (CRO), Institutional Review Board (IRB), the Ethics Committee, and U.S. Food and Drug Administration (FDA) to review his/her relevant medical records.~Exclusion Criteria:~* Subjects who withdrew or were withdrawn from study 012-VWAV06.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Graft, Vascular Wrap (Type: ACTIVE_COMPARATOR): Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
- Graft (Type: PLACEBO_COMPARATOR): Lifespan® ePTFE Vascular Graft Only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* In-patients with probable or definite ALS, ages 18 - 90, staying on the neurology floor of Hahnemann Hospital~Exclusion Criteria:~* In-patients who do not meet the criteria of the diagnosis of ALS.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- ALS (Type: None): Subjects having either definite or probable ALS by El Escorial Criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues